Medicis Pharmaceutical Corp. (MRX) Reports Slightly Better-Than-Expected Q4 Results
Tweet
Share
E-mailGet Alerts MRX Hot Sheet
Price: $72.27 +1.70%
Financial Fact:
Net product revenues: 179.13M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Net product revenues: 179.13M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Medicis Pharmaceutical Corp. (NYSE: MRX) reported Q4 EPS of $0.56, $0.01 better than the analyst estimate of $0.55. Revenue for the quarter came in at $180.7 million versus the consensus estimate of $179.2 million.
For earnings history and earnings-related data on Medicis Pharmaceutical Corp. (MRX) click here.
For earnings history and earnings-related data on Medicis Pharmaceutical Corp. (MRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30
- Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
